Search Results
Search for other papers by Fan Zhang in
Google Scholar
PubMed
Search for other papers by Jian Chen in
Google Scholar
PubMed
Search for other papers by Xinyue Lin in
Google Scholar
PubMed
Search for other papers by Shiqiao Peng in
Google Scholar
PubMed
Search for other papers by Xiaohui Yu in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
Objective
Maternal hypothyroidism during pregnancy can affect the neurodevelopment of their offspring. This study aimed to investigate the effects of maternal subclinical hypothyroidism (SCH) on spatial learning and memory, and its relationship with the apoptotic factors in cerebral cortex of the offspring.
Methods
Female adult Wistar rats were randomly divided into three groups (n = 15 per group): control (CON) group, SCH group and overt hypothyroidism (OH) group. Spatial learning and memory in the offspring were evaluated by long-term potentiation (LTP) and Morris water-maze (MWM) test. The protein expression of the p75 neurotrophin receptor (p75NTR), phospho-c-Jun N-terminal kinase (p-JNK), the pro-apoptotic protein p53 and Bax were detected by Western blotting.
Results
The Pups in the SCH and OH groups showed longer escape latencies in the MWM and decreased field-excitatory post synaptic potentials in LTP tests compared with those in the CON group. p75NTR, p-JNK, p53 and Bax expression levels in the cerebral cortex increased in pups in the SCH and OH groups compared with those in the CON group.
Conclusions
Maternal SCH during pregnancy may impair spatial learning and memory in the offspring and may be associated with the increased apoptosis in the cerebral cortex.
Institution of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Xiao Zong in
Google Scholar
PubMed
Institution of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Qin Fan in
Google Scholar
PubMed
Institution of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Hang Zhang in
Google Scholar
PubMed
Institution of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Qian Yang in
Google Scholar
PubMed
Institution of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Hongyang Xie in
Google Scholar
PubMed
Search for other papers by Qiujing Chen in
Google Scholar
PubMed
Search for other papers by Ruiyan Zhang in
Google Scholar
PubMed
Search for other papers by Rong Tao in
Google Scholar
PubMed
To explore the relationship between soluble ST2 (sST2) and metabolic syndrome (MetS) and determine whether sST2 levels can predict the presence and severity of MetS. We evaluated 550 consecutive subjects (58.91 ± 9.69 years, 50% male) with or without MetS from the Department of Vascular & Cardiology, Shanghai Jiao Tong University-Affiliated Ruijin Hospital. Serum sST2 concentrations were measured. The participants were divided into three groups according to the sST2 tertiles. Univariate and multivariable logistic regression models were used to evaluate the association between serum sST2 concentrations and the presence of MetS. Serum sST2 concentrations were significantly higher in the MetS group than in those in the no MetS group (14.80 ± 7.01 vs 11.58 ± 6.41 ng/mL, P < 0.01). Subjects with more MetS components showed higher levels of sST2. sST2 was associated with the occurrence of MetS after multivariable adjustment as a continuous log-transformed variable (per 1 SD, odds ratio (OR): 1.42, 95% CI: 1.13–1.80, P < 0.01). Subgroup analysis showed that individuals with MetS have significantly higher levels of sST2 than those without MetS regardless of sex and age. High serum sST2 levels were significantly and independently associated with the presence and severity of MetS. Thus, sST2 levels may be a novel biomarker and clinical predictor of MetS.
Search for other papers by Chenghao Piao in
Google Scholar
PubMed
Search for other papers by Xiaojie Wang in
Google Scholar
PubMed
Search for other papers by Shiqiao Peng in
Google Scholar
PubMed
Search for other papers by Xinyu Guo in
Google Scholar
PubMed
Search for other papers by Hui Zhao in
Google Scholar
PubMed
Search for other papers by Li He in
Google Scholar
PubMed
Search for other papers by Yan Zeng in
Google Scholar
PubMed
Search for other papers by Fan Zhang in
Google Scholar
PubMed
Search for other papers by Kewen Zhu in
Google Scholar
PubMed
Search for other papers by Yiwei Wang in
Google Scholar
PubMed
Objective
Gestational diabetes mellitus (GDM) is characterized by glucose intolerance during gestation. It is associated with a series of maternal and foetal complications. Interleukin (IL)-34 is a recently discovered pro-inflammatory cytokine that functions as a ligand for colony-stimulating factor-1 receptor (CSF-1R). The contribution of IL-34 in the development of multiple chronic inflammatory diseases and autoimmune diseases has been recently discovered. The aim of this study was to evaluate whether IL-34 participates in the pathogenesis of GDM.
Method
A total of 120 women were enrolled in this study, which included 60 GDM patients and age- and sex-matched healthy pregnant women. The expression of IL-34 in serum, cord blood and placental tissues was analysed by ELISA and Western blot assays. The association between IL-34 levels and clinical features was also studied. We additionally evaluated the effect of recombinant mouse IL-34 (rmIL-34) on apoptosis and pancreatic β cell function.
Results
We found that IL-34 expression is highly increased in serum, cord blood and placental tissues in patients with GDM. In addition, there was a positive association between serum IL-34 and insulin resistance and glucose concentrations. Our data also revealed that IL-34 contributes to the apoptosis of pancreatic β cells in GDM caused by CSF-1R. Furthermore, functional studies found that IL-34 inhibited pancreatic β cell function and cell viability, while CSF-1R inhibitor blocked this effect.
Conclusion
IL-34 plays a crucial role in the development of GDM by targeting CSF-1R, insulin production and β cell function.
Search for other papers by Peng Fan in
Google Scholar
PubMed
Search for other papers by Chao-Xia Lu in
Google Scholar
PubMed
Search for other papers by Di Zhang in
Google Scholar
PubMed
Search for other papers by Kun-Qi Yang in
Google Scholar
PubMed
Search for other papers by Pei-Pei Lu in
Google Scholar
PubMed
Search for other papers by Ying Zhang in
Google Scholar
PubMed
Search for other papers by Xu Meng in
Google Scholar
PubMed
Search for other papers by Su-Fang Hao in
Google Scholar
PubMed
Search for other papers by Fang Luo in
Google Scholar
PubMed
Search for other papers by Ya-Xin Liu in
Google Scholar
PubMed
Search for other papers by Hui-Min Zhang in
Google Scholar
PubMed
Search for other papers by Lei Song in
Google Scholar
PubMed
Search for other papers by Jun Cai in
Google Scholar
PubMed
Search for other papers by Xue Zhang in
Google Scholar
PubMed
Search for other papers by Xian-Liang Zhou in
Google Scholar
PubMed
Liddle syndrome (LS), a monogenetic autosomal dominant disorder, is mainly characterized by early-onset hypertension and hypokalemia. Clinically, misdiagnosis or missing diagnosis is common, since clinical phenotypes of LS are variable and nonspecific. We report a family with misdiagnosis of primary aldosteronism (PA), but identify as LS with a pathogenic frameshift mutation of the epithelial sodium channel (ENaC) β subunit. DNA samples were collected from a 32-year-old proband and 31 other relatives in the same family. A designed panel including 41 genes associated with monogenic hypertension was screened using next-generation sequencing. The best candidate disease-causing variants were verified by Sanger sequencing. Genetic analysis of the proband revealed a novel frameshift mutation c.1838delC (p.Pro613Glnfs*675) in exon 13 of SCNN1B. This heterozygous mutation involved the deletion of a cytosine from a string of three consecutive cytosines located at codons 612 to 613 and resulted in deletion of the crucial PY motif and elongation of the β-ENaC protein. The identical mutation was also found in 12 affected family members. Amiloride was effective in alleviating LS for patients. There were no SCNN1A or SCNN1G mutations in this family. Our study emphasizes the importance of considering LS in the differential diagnosis of early-onset hypertension. The identification of a novel frameshift mutation of SCNN1B enriches the genetic spectrum of LS and has allowed treatment of this affected family to prevent severe complications.
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, China
Search for other papers by Xinyuan Zhang in
Google Scholar
PubMed
Search for other papers by Suiyan Li in
Google Scholar
PubMed
Search for other papers by Hongwei Liu in
Google Scholar
PubMed
Search for other papers by Huai Bai in
Google Scholar
PubMed
Search for other papers by Qingqing Liu in
Google Scholar
PubMed
Search for other papers by Chunyi Yang in
Google Scholar
PubMed
Search for other papers by Ping Fan in
Google Scholar
PubMed
Oxidative stress and metabolic disorders are involved in the pathogenesis of polycystic ovary syndrome (PCOS). Heme oxygenase 2 (HMOX2) plays a critical role in preserving heme metabolism as well as in modulating glycolipid metabolism, oxidative stress, and inflammation. This study examined the correlation between HMOX2 G554A (rs1051308) and A-42G (rs2270363) genetic variants with the risk of PCOS and assessed the effects of these genotypes on clinical, hormonal, metabolic, and oxidative stress indices using a case–control design that included 1014 patients with PCOS and 806 control participants. We found that the allelic and genotypic frequencies of the HMOX2 G554A and A-42G polymorphisms were comparable between the PCOS and control groups in Chinese women (P > 0.05). Nevertheless, it was discovered that patients with the AA or AG genotype of A-42G polymorphism had notably elevated levels of estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), LH/FSH ratio, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein (apo)B, and/or apoB/apoA1 ratio than those with the GG genotypes (P < 0.05). Patients with the GG or AG genotype of G554A polymorphism had elevated serum levels of LH, FSH, E2, LH/FSH ratio, TC, HDL-C, LDL-C, apoB, and/or apoB/apoA1 ratio and lower 2-h glucose concentration compared with those with the AA genotype (P < 0.05). Our findings indicate a potential association between the genetic variants and endocrine abnormalities in the reproductive system and metabolic irregularities in glycolipid levels in patients, thus suggesting their potential role in the pathogenesis of PCOS.
Search for other papers by Min Li in
Google Scholar
PubMed
Search for other papers by Ying Chen in
Google Scholar
PubMed
Search for other papers by Jingjing Jiang in
Google Scholar
PubMed
Search for other papers by Yan Lu in
Google Scholar
PubMed
Search for other papers by Zhiyi Song in
Google Scholar
PubMed
Search for other papers by Shengjie Zhang in
Google Scholar
PubMed
Search for other papers by Chao Sun in
Google Scholar
PubMed
Search for other papers by Hao Ying in
Google Scholar
PubMed
Search for other papers by Xiaofang Fan in
Google Scholar
PubMed
Search for other papers by Yuping Song in
Google Scholar
PubMed
Search for other papers by Jialin Yang in
Google Scholar
PubMed
Search for other papers by Lin Zhao in
Google Scholar
PubMed
Objective
Recent studies have shown that neuregulin 4 (Nrg4), a member of the epidermal growth factor (EGF) family of extracellular ligands, plays an important role in the prevention of obesity, insulin resistance and nonalcoholic fatty liver disease (NAFLD). Considering that thyroid hormone (TH) has profound effects on whole-body energy metabolism, we speculate that circulating Nrg4 levels might be altered in patients with hyperthyroidism.
Design and methods
A total of 129 hyperthyroid patients and 100 healthy subjects were recruited. Of them, 39 hyperthyroid patients received thionamide treatment for 3 months until euthyroidism. Serum Nrg4 levels were determined using the ELISA method. To further confirm the relationship between TH and Nrg4, C57BL/6 mice were treated with T3 and quantitative real-time PCR was performed to detect Nrg4 gene expression.
Results
Serum Nrg4 levels were significantly elevated in hyperthyroid patients as compared with normal controls (3.84 ± 1.63 vs 2.21 ± 1.04 ng/mL, P < 0.001). After achieving euthyroidism by thionamide treatment, serum Nrg4 levels dropped markedly from 3.57 ± 1.26 to 1.94 ± 0.72 ng/ml (P < 0.001). After adjustment for potential confounders, serum Nrg4 levels were independently associated with hyperthyroidism. The upregulation of Nrg4 expression in the livers and white adipose tissues by T3 was further confirmed by animal and cell culture experiments.
Conclusions
Serum Nrg4 levels were increased in patients with hyperthyroidism. The liver and white adipose tissue might be primary sources contributing to elevated serum Nrg4 concentrations.
Medical Science Laboratory, Children’s Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China
Department of pathology, Children’s Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China
Search for other papers by Chunyun Fu in
Google Scholar
PubMed
Search for other papers by Shiyu Luo in
Google Scholar
PubMed
Department of pathology, Children’s Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, People’s Republic of China
Search for other papers by Yingfeng Li in
Google Scholar
PubMed
Search for other papers by Qifei Li in
Google Scholar
PubMed
Search for other papers by Xuehua Hu in
Google Scholar
PubMed
Search for other papers by Mengting Li in
Google Scholar
PubMed
Search for other papers by Yue Zhang in
Google Scholar
PubMed
Search for other papers by Jiasun Su in
Google Scholar
PubMed
Search for other papers by Xuyun Hu in
Google Scholar
PubMed
Search for other papers by Yun Chen in
Google Scholar
PubMed
Search for other papers by Jin Wang in
Google Scholar
PubMed
Search for other papers by Bobo Xie in
Google Scholar
PubMed
Search for other papers by Jingsi Luo in
Google Scholar
PubMed
Search for other papers by Xin Fan in
Google Scholar
PubMed
Search for other papers by Shaoke Chen in
Google Scholar
PubMed
Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Search for other papers by Yiping Shen in
Google Scholar
PubMed
Background
The incidence of congenital hypothyroidism (CH) differs significantly among different ethnicities and regions, and early differentiation of transient CH is important to avoid unnecessary prolonged treatment with L-T4.
Objective
To investigate the incidence of CH based on the newborn screening program in Guangxi Zhuang Autonomous Region, China, and to analyze the predictors that might allow for an early differentiation between permanent (P) and transient (T) CH.
Design and methods
Data from newborn screening program over a seven-year period (January 2009 to January 2016) at Guangxi Maternal and Child Health Hospital are analyzed. Blood samples were collected on filter paper between 3 and 7 days after birth, and TSH level was measured by time-resolved fluorescence assay. Individuals with increased TSH (TSH ≥ 8 IU/L) levels detected by newborn screening were recalled for further evaluation. Serum TSH, FT3 and FT4 were determined by electrochemiluminescence assay using venous blood samples. Diagnosis of CH is based on elevated TSH levels (>10 IU/L) and decreased FT4 levels (<12 pmol/L). Patients with elevated TSH levels and normal FT4 levels were diagnosed as hyperthyrotropinemia. Permanent or transient CH was determined by using the results of thyroid function tests after temporary withdrawal of L-T4 therapy at approximately 2–3 years of age.
Results
Among 1,238,340 infants in the newborn screening program, 14,443 individuals were recalled for reevaluation (re-call rate 1.18%), 911 and 731 individuals were subsequently determined to have hyperthyrotropinemia and CH respectively; thus, a prevalence of 1:1359 and 1:1694 for hyperthyrotropinemia and CH. Of the 731 patients with CH, 161 patients were diagnosed with permanent CH (PCH), and 159 patients were diagnosed with transient CH (TCH), the other 411 patients are too young to determine their subtypes. Patients with PCH required an increasing dose of L-T4 during the first few years, whereas patients with TCH required a decreased dose of L-T4. The TSH levels at diagnosis and the dose of L-T4 used were significantly higher in PCH cases than in transient cases. The FT4 levels at diagnosis were significantly lower in PCH cases than in TCH cases. The TSH levels at diagnosis, FT4 levels at diagnosis and L-T4 doses at 90 days were evaluated as predictors for differentiating PCH and TCH, and their accuracy at their respective optimal cutoffs were determined to be 60.6%, 66.7% and 93.9%, respectively.
Conclusions
The CH incidence in Guangxi Zhuang Autonomous Region is slightly higher (1:1694) compared to the worldwide levels (1/2000–1/4000). The PCH and TCH ratio is close to 1; thus, the estimated PCH incidence is 1/3388, which is similar to reported worldwide average incidence (1/3000). The L-T4 dose required at 90 days (>30 μg/day) has the highest predictive value for PCH. Earlier differentiation of PCH and TCH helps to determine appropriate treatment course.
